A Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma following Myeloablative Therapy and Autologous Stem Cell Transplant (Companion Study to A3973)
This partially randomized phase III trial studies isotretinoin with monoclonal antibody
Ch14.18, aldesleukin, and sargramostim to see how well it works compared to isotretinoin
alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in
chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as monoclonal antibody Ch14.18, can block tumor growth in different ways. Some block
the ability of tumors to grow and spread. Others find tumor cells and help kill them or
deliver tumor-killing substances to them. Aldesleukin and sargramostim may stimulate a
person''s white blood cells to kill cancer cells. It is not yet known if chemotherapy is more
effective with or without monoclonal antibody Ch14.18, aldesleukin, and sargramostim
following stem cell transplant in treating neuroblastoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.